|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Patani N, Martin LA and Dowsett M:
Biomarkers for the clinical management of breast cancer:
international perspective. Int J Cancer. 133:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar
|
|
5
|
Yang XR, Chang-Claude J, Goode EL, et al:
Associations of breast cancer risk factors with tumor subtypes: a
pooled analysis from the Breast Cancer Association Consortium
studies. J Natl Cancer Inst. 103:250–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Muss HB: Coming of age: breast cancer in
seniors. Oncologist. 16(Suppl 1): S79–S87. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma H, Wang Y, Sullivan-Halley J, et al:
Use of four biomarkers to evaluate the risk of breast cancer
subtypes in the women’s contraceptive and reproductive experiences
study. Cancer Res. 70:575–587. 2010.
|
|
8
|
Shubbar E, Helou K, Kovács A, et al: High
levels of γ-glutamyl hydrolase (GGH) are associated with poor
prognosis and unfavorable clinical outcomes in invasive breast
cancer. BMC Cancer. 13:472013.
|
|
9
|
Tian W, Chen J, He H and Deng Y: MicroRNAs
and drug resistance of breast cancer: basic evidence and clinical
applications. Clin Transl Oncol. 15:335–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ombra MN, Di Santi A, Abbondanza C,
Migliaccio A, Avvedimento EV and Perillo B: Retinoic acid impairs
estrogen signaling in breast cancer cells by interfering with
activation of LSD1 via PKA. Biochim Biophys Acta. 1829:480–486.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fasching PA, Heusinger K, Haeberle L, et
al: Ki67, chemotherapy response, and prognosis in breast cancer
patients receiving neoadjuvant treatment. BMC Cancer. 11:4862011.
View Article : Google Scholar
|
|
12
|
Sharan S, Nikhil K and Roy P: Effects of
low dose treatment of tributyltin on the regulation of estrogen
receptor functions in MCF-7 cells. Toxicol Appl Pharmacol.
269:176–186. 2013. View Article : Google Scholar
|
|
13
|
Yan Y, Liu H, Wen H, et al: The novel
estrogen receptor GPER regulates the migration and invasion of
ovarian cancer cells. Mol Cell Biochem. 378:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oh Y and Chung KC: Zinc finger protein 131
inhibits estrogen signaling by suppressing estrogen receptor α
homo-dimerization. Biochem Biophys Res Commun. 430:400–405.
2013.PubMed/NCBI
|
|
15
|
Komm BS and Mirkin S: Evolution of the
tissue selective estrogen complex (TSEC). J Cell Physiol.
228:1423–1427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng Q, Chang JT, Geradts J, et al:
Amplification and high-level expression of heat shock protein 90
marks aggressive phenotypes of human epidermal growth factor
receptor 2 negative breast cancer. Breast Cancer Res. 14:R622012.
View Article : Google Scholar
|
|
17
|
Coughlan N, Thillainadesan G, Andrews J,
Isovic M and Torchia J: β-Estradiol-dependent activation of the
JAK/STAT pathway requires p/CIP and CARM1. Biochim Biophys Acta-Mol
Cell Res. 1833:1463–1475. 2013.
|
|
18
|
Sengupta S, Obiorah I, Maximov PY, Curpan
R and Jordan VC: Molecular mechanism of action of bisphenol and
bisphenol A mediated by oestrogen receptor alpha in growth and
apoptosis of breast cancer cells. Br J Pharmacol. 169:167–178.
2013. View Article : Google Scholar
|
|
19
|
Levin ER: Integration of the extranuclear
and nuclear actions of estrogen. Mol Endocrinol. 19:1951–1959.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pirman DA, Efuet E, Ding XP, et al:
Changes in cancer cell metabolism revealed by direct sample
analysis with MALDI mass spectrometry. PLoS One. 8:e613792013.
View Article : Google Scholar
|
|
21
|
Cornett DS, Reyzer ML, Chaurand P and
Caprioli RM: MALDI imaging mass spectrometry: molecular snapshots
of biochemical systems. Nat Methods. 4:828–833. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang HS, Wu HM, Cheng BH, et al:
Functional analyses of endometriosis-related polymorphisms in the
estrogen synthesis and metabolism-related genes. PLoS One.
7:e473742012. View Article : Google Scholar
|
|
23
|
Srinivasan S, Nwachukwu JC, Parent AA, et
al: Ligand-binding dynamics rewire cellular signaling via estrogen
receptor-α. Nat Chem Biol. 9:326–332. 2013.PubMed/NCBI
|
|
24
|
Aust S, Horak P, Pils D, et al: The
prognostic value of estrogen receptor beta and proline-, glutamic
acid- and leucine-rich protein 1 (PELP1) expression in ovarian
cancer. BMC Cancer. 13:1152013. View Article : Google Scholar
|
|
25
|
Borjesson AE, Farman HH, Engdahl C, et al:
The role of activation functions 1 and 2 of estrogen receptor-α for
the effects of estradiol and selective estrogen receptor modulators
in male mice. J Bone Miner Res. 28:1117–1126. 2013.
|
|
26
|
Zeng H, Wu JC, Bedford MT, et al: A
TR-FRET-based functional assay for screening activators of CARM1.
Chembiochem. 14:827–835. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meric-Bernstam F, Gutierrez-Barrera AM,
Litton J, et al: Genotype in BRCA-associated breast cancers. Breast
J. 19:87–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang H, Teng R, Wang Q, et al:
Transcriptional analysis of estrogen receptor alpha variant mRNAs
in colorectal cancers and their matched normal colorectal tissues.
J Steroid Biochem Mol Biol. 112:20–24. 2008. View Article : Google Scholar
|
|
29
|
Wang J, Li J, Fang R, Xie S, Wang L and Xu
C: Expression of ERα36 in gastric cancer samples and their matched
normal tissues. Oncol Lett. 3:172–175. 2012.
|
|
30
|
Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY and
Qiao J: ER-α36, a novel variant of estrogen receptor α, is involved
in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet
Gynecol. 205:227.e1–e6. 2011.
|
|
31
|
Kammerer M, Gutzwiller S, Stauffer D,
Delhon I, Seltenmeyer Y and Fournier B: Estrogen receptor α (ERα)
and estrogen related receptor α (ERRα) are both transcriptional
regulators of the Runx2-I isoform. Mol Cell Endocrinol.
369:150–160. 2013.
|
|
32
|
Gamucci T, Vaccaro A, Ciancola F, et al:
Recurrence risk in small, node-negative, early breast cancer: a
multicenter retrospective analysis. J Cancer Res Clin Oncol.
139:853–860. 2013. View Article : Google Scholar
|
|
33
|
Althuis MD, Fergenbaum JH, Garcia-Closas
M, Brinton LA, Madigan MP and Sherman ME: Etiology of hormone
receptor-defined breast cancer: a systematic review of the
literature. Cancer Epidemiol Biomarkers Prev. 13:1558–1568.
2004.PubMed/NCBI
|
|
34
|
Thrane S, Lykkesfeldt AE, Larsen MS,
Sorensen BS and Yde CW: Estrogen receptor α is the major driving
factor for growth in tamoxifen-resistant breast cancer and
supported by HER/ERK signaling. Breast Cancer Res Treat. 139:71–80.
2013.
|
|
35
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ramirez-Ardila DE, Helmijr JC, Look MP, et
al: Hotspot mutations in PIK3CA associate with first-line treatment
outcome for aromatase inhibitors but not for tamoxifen. Breast
Cancer Res Treat. 139:39–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hiscox S, Davies EL and Barrett-Lee P:
Aromatase inhibitors in breast cancer. Maturitas. 63:275–279. 2009.
View Article : Google Scholar
|
|
38
|
Hodgkinson VC, Agarwal V, El Fadl D, et
al: Pilot and feasibility study: comparative proteomic analysis by
2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative
biomarkers of response to neoadjuvant chemotherapy in ER-positive
breast cancer. J Proteomics. 75:2745–2752. 2012. View Article : Google Scholar
|
|
39
|
Kim SI, Sohn J, Koo JS, Park SH, Park HS
and Park BW: Molecular subtypes and tumor response to neoadjuvant
chemotherapy in patients with locally advanced breast cancer.
Oncology. 79:324–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haddock CL, Holtz B, Senzer N and
Nemunaitis J: Applications of HPLC-MALDI-TOF MS/MS phosphoproteomic
analysis in oncological clinical diagnostics. Curr Proteomics.
8:153–167. 2011. View Article : Google Scholar
|
|
41
|
Tangjitgamol S, Tanvanich S,
Srijaipracharoen S and Manusirivithaya S: Expression of estrogen
receptor, progesterone receptor, and Her-2/neu in primary and
extra-corporeal endometrial cancer. Histol Histopathol. 28:787–794.
2013.PubMed/NCBI
|
|
42
|
Alkner S, Bendahl PO, Grabau D, et al: The
role of AIB1 and PAX2 in primary breast cancer: validation of AIB1
as a negative prognostic factor. Ann Oncol. 24:1244–1252. 2013.
View Article : Google Scholar
|
|
43
|
Seferina SC, Nap M, van den Berkmortel F,
Wals J, Voogd AC and Tjan-Heijnen VC: Reliability of receptor
assessment on core needle biopsy in breast cancer patients. Tumour
Biol. 34:987–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wik E, Ræder MB, Krakstad C, et al: Lack
of estrogen receptor-α is associated with epithelial-mesenchymal
transition and PI3K alterations in endometrial carcinoma. Clin
Cancer Res. 19:1094–1105. 2013.
|
|
45
|
Kinsella MD, Birdsong GG, Siddiqui MT,
Cohen C and Hanley KZ: Immunohistochemical detection of estrogen
receptor, progesterone receptor and human epidermal growth factor
receptor 2 in formalin-fixed breast carcinoma cell block
preparations: correlation of results to corresponding tissue block
(needle core and excision) samples. Diagn Cytopathol. 41:192–198.
2013.
|
|
46
|
Sang QX, Man YG, Sung YM, et al:
Non-receptor tyrosine kinase 2 reaches its lowest expression levels
in human breast cancer during regional nodal metastasis. Clin Exp
Metastasis. 29:143–153. 2012. View Article : Google Scholar
|
|
47
|
Jin Y, Zhang X, Lu D, et al:
Histopathological and proteomic analysis of hepatic tissue from
adult male zebrafish exposed to 17β-estradiol. Environ Toxicol
Pharmacol. 29:91–95. 2010.PubMed/NCBI
|
|
48
|
Pietrowska M, Marczak L, Polanska J, et
al: Mass spectrometry-based serum proteome pattern analysis in
molecular diagnostics of early stage breast cancer. J Transl Med.
7:602009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bouchal P, Dvorakova M, Scherl A, Garbis
SD, Nenutil R and Vojtesek B: Intact protein profiling in breast
cancer biomarker discovery: protein identification issue and the
solutions based on 3D protein separation, bottom-up and top-down
mass spectrometry. Proteomics. 13:1053–1058. 2013. View Article : Google Scholar
|
|
50
|
Nalvarte I, Schwend T and Gustafsson JA:
Proteomics analysis of the estrogen receptor alpha receptosome. Mol
Cell Proteomics. 9:1411–1422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Atsriku C, Benz CC, Scott GK, Gibson BW
and Baldwin MA: Quantification of cysteine oxidation in human
estrogen receptor by mass spectrometry. Anal Chem. 79:3083–3090.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cornett DS, Mobley JA, Dias EC, et al: A
novel histology-directed strategy for MALDI-MS tissue profiling
that improves throughput and cellular specificity in human breast
cancer. Mol Cell Proteomics. 5:1975–1983. 2006. View Article : Google Scholar
|
|
53
|
Kabbage M, Trimeche M, Bergaoui S, et al:
Calreticulin expression in infiltrating ductal breast carcinomas:
relationships with disease progression and humoral immune
responses. Tumour Biol. 34:1177–1188. 2013. View Article : Google Scholar
|
|
54
|
Castilla MÁ, Diaz-Martin J, Sarrió D, et
al: MicroRNA-200 family modulation in distinct breast cancer
phenotypes. PLoS One. 7:e477092012.PubMed/NCBI
|
|
55
|
Paramanik V and Thakur MK: Estrogen
receptor β and its domains interact with casein kinase 2,
phosphokinase C, and N-myristoylation sites of mitochondrial and
nuclear proteins in mouse brain. J Biol Chem. 287:22305–22316.
2012.
|
|
56
|
Bovet C, Plet B, Ruff M, et al: Towards
high-throughput identification of endocrine disrupting compounds
with mass spectrometry. Toxicol In Vitro. 23:704–709. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Collodoro M, Lemaire P, Eppe G, et al:
Identification and quantification of concentration-dependent
biomarkers in MCF-7/BOS cells exposed to 17β-estradiol by 2-D DIGE
and label-free proteomics. J Proteomics. 75:4555–4569.
2012.PubMed/NCBI
|
|
58
|
Lai TC, Chou HC, Chen YW, et al:
Secretomic and proteomic analysis of potential breast cancer
markers by two-dimensional differential gel electrophoresis. J
Proteome Res. 9:1302–1322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Obazee O, Justenhoven C, Winter S, et al:
Confirmation of the reduction of hormone replacement
therapy-related breast cancer risk for carriers of the
HSD17B1_937_G variant. Breast Cancer Res Treat. 138:543–548. 2013.
View Article : Google Scholar : PubMed/NCBI
|
